Article Figures & Data
Figures
- Figure 1.
KPC cells show expression pancreatic TIC markers. A, representative CD133 expression; B, CD24+/CD44+/ESA+ expression; and C, Aldh1 activity in KPC cells. D, fold change in mRNA expression of a number of TIC markers in KPC cells compared with normal ductal cells.
- Figure 2.
CD133+ subset in KPC cells expressed TIC markers associated with other cell types. A, enrichment of KPC CD133+ population by MACS; B, CD44+CD24+ESA+ population within CD133− cells and CD133+ population. C, Aldh1 activity within CD133− cells and CD133+ population. D, coexpression of CD133+/Aldh1+ by immunofluorescence.
- Figure 3.
CD133+ cells formed serially transplantable tumors in immune-competent mice. A, tumor progression with different numbers of CD133+ cells. B, representative pictures of C57BL6 mice showing tumor from 10 CD133+ cells, whereas CD133− and unsorted KPC did not form tumors with this number. CD133+ cells showed early tumorigenesis in an orthotopic model: tumor progression in an orthotopic model of pancreatic cancer showed tumor formation in CD133+ cells as early as 20 days as compared with unsorted cells that did not form tumors (C). H&E staining showing histology of tumors in an orthotopic model (D).
- Figure 4.
CD133 cells have higher expression of prosurvival proteins. Fold change in mRNA expression of (A) Bcl-2 and Survivin, (B) developmental markers, and (C) heat shock genes of CD133+ compared with CD133− KPC cells. NF-κB activity in CD133+ and CD133− cells (D).Wild-type and mutant oligos were used as specificity controls for NF-κB binding assay.
- Figure 5.
KPC cells respond to triptolide. A, viability of CD133+ and CD133− cells with triptolide, paclitaxel, 5FU, and gemcitabine. B, tumor progression after Minnelide treatment compared with untreated tumor. Minnelide reduces TIC population in vivo. C, expression of CD133 in primary KPC tumors and CD133+ implanted tumors after treatment with Minnelide, (D) NF-κB activity in Minnelide-treated and -untreated tumors from KPC primary tumors and CD133+ cell implanted tumors. A total of 4 to 5 tumors were analyzed for each experiment.
Tables
- Table 1.
TIC markers cells in different pancreatic tumors and cell lines
Nature of sample CD133 (% positive) CD44/24/ESA (% positive) Aldh activity (net) (% positive) KPC001 Cell line 8% (±1.8%) 4.3% (±1.6%) 2.2% (±1.1%) KPC023 Cell line 7.1% (±1.2%) 3.8% (±1.2%) 1.8% (±0.8%) KPC883 Tumor 6.9% 4.1% 0.9% KPC820 Tumor 8.2% 3.2% 1.1% KPC793 Tumor 7.8% 2.6% 0.8% AsKPC883 Ascitis 2.2% 0 0 AsKPC820 Ascitis 2.8% 0 0 AsKPC793 Ascitis 2.1% 0 0 Liver001 Cell line 2.4% (±0.7%) 0.5% (±0.2%) 0.8 (±0.4%) hPDX1 Tumor xenograft 4.2% (±1.6%) 1.2% (±0.3%) 2.8% (±1.2%) hPDX2 Tumor xenograft 3.5% (±1.4%) 0.8% (±0.3%) 1.1% (±0.9%) hPDX3 Tumor xenograft 2.8% (±0.9%) 0.3% (±0.2%) 0.9% (±0.4%) hPDX4 Tumor (fresh) 4.5% 0.2% 0.8%
Supplementary Data
Files in this Data Supplement:
- Supplementary Methods, Figure Legends, Tables 1 - 2 - PDF file - 124KB, Supplementary Table 1. Tumorigenicity of CD133+ population, CD133 - population and unsorted KPC cells. Supplementary Table 2. Recent therapeutic compounds tested against pancreatic tumor initialing cells.
- Supplementary Figure 1 - PDF file - 644KB, Characterizing KPC tumor initiating cells.
- Supplementary Figure 2 - PDF file - 1384KB, CD133+ population from human tumor xenografts in SCID mice showed tumor formation.
- Supplementary Figure 3 - PDF file - 184KB, CD133+ population formed serially transplantable tumors.
- Supplementary Figure 4 - PDF file - 998KB, Immunohistochemistry of tumors.
- Supplementary Figure 5 - PDF file - 614KB, Illumina microarray for CD133+ and CD133- cells.
- Supplementary Figure 6 - PDF file - 1784KB, Representative slides from tumors treated (B) and untreated (A) with Minnelide.
Volume 20, Issue 9
